Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 29, 2024

BUY
$87.78 - $105.45 $3.51 Million - $4.21 Million
39,954 Added 9.76%
449,302 $46.5 Million
Q3 2023

Oct 30, 2023

BUY
$90.94 - $199.54 $35.1 Million - $76.9 Million
385,439 Added 1612.11%
409,348 $37.2 Million
Q2 2023

Aug 10, 2023

BUY
$155.98 - $172.65 $2.43 Million - $2.69 Million
15,609 Added 188.06%
23,909 $3.87 Million
Q2 2023

Jul 24, 2023

SELL
$155.98 - $172.65 $3.07 Million - $3.39 Million
-19,659 Reduced 70.31%
8,300 $1.34 Million
Q1 2023

May 11, 2023

SELL
$132.34 - $159.14 $673,610 - $810,022
-5,090 Reduced 15.4%
27,959 $4.45 Million
Q4 2022

Feb 06, 2023

SELL
$102.55 - $135.33 $1.77 Million - $2.33 Million
-17,250 Reduced 34.29%
33,049 $4.47 Million
Q3 2022

Oct 31, 2022

SELL
$95.28 - $116.93 $36,206 - $44,433
-380 Reduced 0.75%
50,299 $5.04 Million
Q2 2022

Aug 01, 2022

SELL
$103.24 - $121.81 $258,409 - $304,890
-2,503 Reduced 4.71%
50,679 $5.63 Million
Q1 2022

May 09, 2022

SELL
$93.1 - $112.54 $1.64 Million - $1.99 Million
-17,662 Reduced 24.93%
53,182 $5.95 Million
Q4 2021

Feb 08, 2022

SELL
$95.88 - $117.08 $127,232 - $155,365
-1,327 Reduced 1.84%
70,844 $7.9 Million
Q3 2021

Nov 03, 2021

BUY
$84.42 - $106.62 $2.44 Million - $3.08 Million
28,927 Added 66.89%
72,171 $6.93 Million
Q2 2021

Aug 05, 2021

BUY
$67.66 - $84.76 $624,772 - $782,673
9,234 Added 27.15%
43,244 $3.62 Million
Q1 2021

May 06, 2021

BUY
$67.06 - $75.82 $787,955 - $890,884
11,750 Added 52.79%
34,010 $2.4 Million
Q2 2020

Aug 10, 2020

BUY
$58.54 - $67.94 $1.3 Million - $1.51 Million
22,260 New
22,260 $1.46 Million

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $237B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Meitav Dash Investments LTD Portfolio

Follow Meitav Dash Investments LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meitav Dash Investments LTD, based on Form 13F filings with the SEC.

News

Stay updated on Meitav Dash Investments LTD with notifications on news.